ManagementSilence Therapeutics is led by a strong senior management team with a proven track record in drug development and successful team leadership.
Ali Mortazavi joined Silence in August 2012 as director of corporate strategy and became chief executive in May 2013. He engineered two fundraisings last year to raise £11m for the company and spearheaded the £19m placing completed in April 2013.
He has over 17 years of in financial services. He started his career as a Technology Analyst at Duncan Lawrie then Credit Lyonnais Securities. In 2001, he co-founded Evolution Securities and ran the principal trading and market making arm, leaving in 2008. He has extensive experience in small companies and has had significant stakes in UK listed technology/biotech ventures.
Chief Operating Officer
Annie joined the company in May 2013. Annie has 14 years of experience in the healthcare industry, in equity research and consulting. While in equity research, Annie covered a wide range of European and U.S. healthcare stocks with a diverse range of market capitalization, business models, and therapeutic focus.
Annie moved to London with JPMorgan when she transferred from the US Large Cap Pharma research team in New York to lead the European Biotechnology research efforts in London. After JPMorgan, Annie worked in research for boutique banks and was involved in fundraisings for small European healthcare companies totalling over €200 million. Annie then founded a consultancy where she advised a number of biotechnology companies in corporate development and communications with the investor community.
TIM FREEBORN BA ACA
Finance Director and Company Secretary
Tim joined the company in August 2012 and became full time in October. Previously he was head of research at Xcap Securities and an analyst at Evolution Securities. After qualifying as a chartered accountant he left practice to become a journalist. For 12 years he worked in the Daily Mail City Office covering biotech, electronics and real estate. Tim gained a BA in Philosophy at University College London.
DR. JÖRG KAUFMANN
Chief Scientific Officer
Dr. Kaufmann possesses more than 14 years of biotechnology industry experience in both the United States and Europe. Since joining Silence in 2000, he has served as both senior and associate director, technologies at the Company’s Berlin location. Prior to joining Silence, Dr. Kaufmann was a senior scientist at Chiron Corporation, where he was responsible for leading one of the company’s molecular biology research groups focused on breast cancer.
From 1996-1997 he served as a group leader at the Institute of Tumour Biology (IMT) in Marburg, Germany. Dr. Kaufmann was a postdoctoral fellow at the Howard Hughes Medical Institute, University of California, Los Angeles and received his Ph.D. in molecular biology from the Philipps University Marburg.
Chief Medical Officer
Dr Michael Khan BSc, MBBS, PhD, FRCP is an Associate Professor of Medicine at the University of Warwick and a Consultant Physician at University Hospitals. He trained in medicine at Guy's and King's in London and completed specialist training at University College London, Middlesex and Whittington Hospitals. He studied for his PhD at UCL.
He is a highly cited researcher and experienced clinician with a long track record in metabolic medicine and cancer biology research as well as in the running of clinical trials. He has written several books on diabetes, cholesterol problems and cancer biology and teaches postgraduates and undergraduates in medicine and biological sciences in these areas.
He is a previous Head of Molecular Medicine at Warwick University and has held numerous research grants in cell and molecular biology. He and co-workers have made important contributions to further understanding of cancer cell biology and diabetes and are working on identifying novel tissue-based biomarkers for colorectal cancer and the development of novel diagnostic tools. He is a fellow of the Royal College of Physicians of London and a member of the Association of Physicians, HEART-UK and Diabetes UK and has acted as an expert advisor to numerous National and International Organisations in both the public and private sectors.